Search

Your search keyword '"Luca, Ceriani"' showing total 10 results
Start Over Author "Luca, Ceriani" Journal hematological oncology
10 results on '"Luca, Ceriani"'

1. Sciatic pain by neurolymphomatosis as initial presentation of disseminated diffuse large B cell lymphoma involving the testis and the CNS

Author

Esteban Ciliberti, Georg Stussi, Emanuele Zucca, Luca Ceriani, and Davide Facchinelli

Subjects
Cancer Research, Pathology, medicine.medical_specialty, Oncology, business.industry, medicine, Hematology, General Medicine, Presentation (obstetrics), medicine.disease, business, Diffuse large B-cell lymphoma, Lymphoma
Published
2020
Full Text
View/download PDF

2. DEVELOPMENT AND VALIDATION OF A PET RADIOMICS PROGNOSTIC MODEL FOR DIFFUSE LARGE B CELL LYMPHOMA

Author

Luciano Cascione, Stefan Dirnhofer, Andrea Bruno, Luca Giovanella, F. Esposito, Giuseppe Gritti, Federico Dalmasso, Lisa Milan, Alessandro Rambaldi, S. Chauvie, Christoph Mamot, Stefanie Hayoz, Emanuele Zucca, Säm Schär, and Luca Ceriani

Subjects
Cancer Research, Oncology, Radiomics, business.industry, Prognostic model, Cancer research, Medicine, Hematology, General Medicine, business, medicine.disease, Diffuse large B-cell lymphoma
Published
2021
Full Text
View/download PDF

3. GENETIC AND PHENOTYPIC ATTRIBUTES OF SPLENIC MARGINAL ZONE LYMPHOMA

Author

D. Piffaretti, Manuela Mollejo, L. Terzi di Bergamo, M. G. Cittone, Liliana Devizzi, Guido Ghilardi, Estella Matutes, Elena Sabattini, Elisa Lucchini, Sílvia Beà, Lydia Scarfò, Sergio Cogliatti, Stefano Pileri, Davide Rossi, M. Án. Piris, Govind Bhagat, Gilles Salles, Armando López-Guillermo, Maria Joao Baptista, Emanuele Zucca, Alden A. Moccia, Alessandra Tucci, Vincenzo Canzonieri, M. Ladetto, Luca Arcaini, Renzo Boldorini, Gabriela Forestieri, Maria Cristina Pirosa, Elias Campo, Alessandro Broccoli, Thomas Tousseyn, Sascha Dietrich, Roberto Marasca, Gianluca Gaidano, Ricardo Koch, Enrico Derenzini, Fabio Facchetti, Juan F. García, Alexandar Tzankov, Michele Merli, Carlo Visco, Hossein Khiabanian, Francesca Guidetti, Franco Cavalli, Arianna Calcinotto, Francesco Passamonti, Thorsten Zenz, Giuseppe Gritti, Julia T. Geyer, Marco Lucioni, M. Ponzoni, M. Faderl, Francesco Bertoni, Anastasios Stathis, Antonino Maiorana, Urban Novak, L. de Leval, Alexandra Traverse-Glehen, Luca Mazzucchelli, Anna Guidetti, Gabriela Bastidas, Véronique Meignin, P. L. Zinzani, Luciano Cascione, Ferdinando Bonfiglio, Giorgio Inghirami, Felicitas Hitz, Stefano Pizzolitto, Alberto J. Arribas, Angela Rita Elia, Elisa Santambrogio, Georg Stussi, Catherine Thieblemont, David Oscier, Marco Paulli, Bernhard Gerber, Umberto Vitolo, Alessio Bruscaggin, Francesco Piazza, Stefan Dirnhofer, W. Wu, Paolo Ghia, Valeria Spina, L. Bonomini, K. Pini, Gustavo Tapia, M. G. Da Silva, Luca Ceriani, Carlos Montalbán, and Adalgisa Condoluci

Subjects
Cancer Research, Pathology, medicine.medical_specialty, Oncology, medicine, Hematology, General Medicine, Splenic marginal zone lymphoma, Biology, medicine.disease, Phenotype
Published
2021
Full Text
View/download PDF

4. CIRCULATING TUMOR DNA IS A PROGNOSTIC BIOMARKER IN CLASSIC HODGKIN LYMPHOMA

Author

Bernhard Gerber, Jan Maciej Zaucha, A. Stasia, E. Borsatti, Carmelo Carlo-Stella, Alessio Bruscaggin, Valeria Spina, Salvatore Annunziata, Anastasios Stathis, M. Kurlapski, F. Cavalli, Alden A. Moccia, Luca Ceriani, Gabriela Forestieri, G. Romanowicz, D. Rossi, Antonello Pinto, Ricardo Koch, Gian Mauro Sacchetti, Gianluca Gaidano, Georg Stussi, Adalgisa Condoluci, Riccardo Moia, S. Chauvie, M. Faderl, Maria Cristina Pirosa, I. Zangrilli, S. Hohaus, K. Pini, S. Gillessen Sommer, M. G. Cittone, Pietro Bulian, M. di Trani, Emanuele Zucca, Marcello Rodari, D. Piffaretti, L. Terzi di Bergamo, and V. Gattei

Subjects
Cancer Research, Oncology, Circulating tumor DNA, business.industry, Cancer research, Hodgkin lymphoma, Medicine, Prognostic biomarker, Hematology, General Medicine, business
Published
2021
Full Text
View/download PDF

5. INTEGRATION OF BASELINE METABOLIC PARAMETERS AND MUTATIONAL PROFILE PREDICTS OUTCOME IN DLBCL PATIENTS. A POST HOC ANALYSIS OF SAKK38/07 STUDY

Author

Alexandar Tzankov, Luca Giovanella, Emanuele Zucca, Luca Ceriani, Stefan Dirnhofer, G Ghilardi, S Genta, Sämi Schär, Stefanie Hayoz, Darius Juskevicius, Christoph Mamot, and Luciano Cascione

Subjects
Oncology, Cancer Research, medicine.medical_specialty, business.industry, Internal medicine, Post-hoc analysis, Medicine, Hematology, General Medicine, Baseline (configuration management), business, Outcome (game theory)
Published
2021
Full Text
View/download PDF

6. SAKK 35/15: A PHASE I TRIAL OF OBINUTUZUMAB IN COMBINATION WITH VENETOCLAX IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA PATIENTS

Author

Ulrich Mey, K. Eckhardt, Francesco Bertoni, D. Kienle, Christiane Pott, Fatime Krasniqi, Emanuele Zucca, Urban Novak, Sämi Schär, Davide Rossi, N. Mach, Anastasios Stathis, Dagmar Hess, Karin Hohloch, Christian Schmidt, Christian Buske, Alden A. Moccia, Felicitas Hitz, Stefanie Hayoz, Michael Unterhalt, Stefan Dirnhofer, Wolfgang Hiddemann, and Luca Ceriani

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Venetoclax, business.industry, Follicular lymphoma, Hematology, General Medicine, medicine.disease, chemistry.chemical_compound, chemistry, Obinutuzumab, Internal medicine, medicine, business
Published
2019
Full Text
View/download PDF

7. INTEGRATION BETWEEN METABOLIC TUMOUR VOLUME AND METABOLIC HETEROGENEITY PREDICTS OUTCOME OF DLBCL LYMPHOMA PATIENTS IN THE SAKK 38/07 STUDY COHORT

Author

Luca Mazzucchelli, Stefanie Hayoz, L. Giovannella, Anastasios Stathis, Alden A. Moccia, Christoph Mamot, S. Ferrari, Andrea Bruno, Stefan Dirnhofer, Emanuele Zucca, Luca Ceriani, Maria Cristina Pirosa, Giuseppe Gritti, Alessandro Rambaldi, and Teresa Ruberto

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Metabolic heterogeneity, business.industry, Hematology, General Medicine, medicine.disease, Outcome (game theory), Lymphoma, Internal medicine, Cohort, Medicine, Tumour volume, business
Published
2019
Full Text
View/download PDF

8. Detection rate of fluorine-18-fluorodeoxyglucose positron emission tomography in patients with marginal zone lymphoma of MALT type: a meta-analysis

Author

Luca Ceriani, Luca Giovanella, Emanuele Zucca, Franco Cavalli, Giorgio Treglia, and Ramin Sadeghi

Subjects
Cancer Research, PET-CT, medicine.diagnostic_test, business.industry, Marginal zone lymphoma, MALT lymphoma, Hematology, General Medicine, medicine.disease, Confidence interval, Lymphoma, Oncology, Positron emission tomography, hemic and lymphatic diseases, Meta-analysis, medicine, Detection rate, Nuclear medicine, business
Abstract

The aim of this article is to meta-analyse published data about the detection rate (DR) of fluorine-18-fluorodeoxyglucose ( 18 F-FDG) positron emission tomography (PET) and PET/computed tomography (CT) in the evaluation of patients with marginal zone lymphoma of the mucosa-associated lymphoid tissue (MALT). A comprehensive literature search of studies published through February 2014 was performed. Pooled DR of 18 F-FDG PET or PET/CT including 95% confidence intervals (95% CI) was calculated on a per-patient-based analysis. Twenty studies including 376 patients with MALT lymphoma were selected. The pooled DR of 18 F-FDG PET or PET/CT was 71% (95% CI: 61–80%). A significant difference between the DR of PET/CT (69%; 95% CI: 61–80%) and that of PET alone (73%; 95% CI: 60–84%) was not demonstrated. A better DR of 18 F-FDG PET or PET/CT in bronchial (94%; 95% CI: 85–99%) and headand-neck (90%; 95% CI: 78–98%) MALT lymphomas compared with gastric (62%; 95% CI: 46–77%) and ocular (49%; 95% CI: 36–63%) MALT lymphomas was found. This meta-analysis demonstra tes that MALT lymphoma is an 18 F-FDG-avid tumour in most of the cases, suggesting a potential clinical role of 18 F-FDG PET or PET/CT in the initial evaluation of these patients. In particular, the DR of 18 F-FDG PET or PET/CT is related to the primary site of the MALT lymphoma. Copyright © 2014 John Wiley & Sons, Ltd.

Published
2014
Full Text
View/download PDF

9. METABOLIC HETEROGENEITY OF BASELINE 18-FDG PET-CT SCAN PREDICTS OUTCOME IN PRIMARY MEDIASTINAL B-CELL LYMPHOMA

Author

Lisa Milan, Luca Giovanella, F. Cavalli, Emanuele Zucca, Marialuisa Martelli, P. Johnson, Anna Ferreri, Luca Ceriani, and A. Di Rocco

Subjects
Cancer Research, medicine.medical_specialty, business.industry, Metabolic heterogeneity, Hematology, General Medicine, medicine.disease, 03 medical and health sciences, 0302 clinical medicine, Oncology, 030220 oncology & carcinogenesis, medicine, Fdg pet ct, Primary mediastinal B-cell lymphoma, Radiology, business, 030215 immunology
Published
2017
Full Text
View/download PDF

10. Detection rate of fluorine-18-fluorodeoxyglucose positron emission tomography in patients with marginal zone lymphoma of MALT type: a meta-analysis

Author

Giorgio, Treglia, Emanuele, Zucca, Ramin, Sadeghi, Franco, Cavalli, Luca, Giovanella, and Luca, Ceriani

Subjects
Fluorodeoxyglucose F18, Positron-Emission Tomography, Humans, Reproducibility of Results, Lymphoma, B-Cell, Marginal Zone, Radiopharmaceuticals, Tomography, X-Ray Computed, Multimodal Imaging
Abstract

The aim of this article is to meta-analyse published data about the detection rate (DR) of fluorine-18-fluorodeoxyglucose ((18) F-FDG) positron emission tomography (PET) and PET/computed tomography (CT) in the evaluation of patients with marginal zone lymphoma of the mucosa-associated lymphoid tissue (MALT). A comprehensive literature search of studies published through February 2014 was performed. Pooled DR of (18) F-FDG PET or PET/CT including 95% confidence intervals (95% CI) was calculated on a per-patient-based analysis. Twenty studies including 376 patients with MALT lymphoma were selected. The pooled DR of (18) F-FDG PET or PET/CT was 71% (95% CI: 61-80%). A significant difference between the DR of PET/CT (69%; 95% CI: 61-80%) and that of PET alone (73%; 95% CI: 60-84%) was not demonstrated. A better DR of (18) F-FDG PET or PET/CT in bronchial (94%; 95% CI: 85-99%) and head-and-neck (90%; 95% CI: 78-98%) MALT lymphomas compared with gastric (62%; 95% CI: 46-77%) and ocular (49%; 95% CI: 36-63%) MALT lymphomas was found. This meta-analysis demonstrates that MALT lymphoma is an (18) F-FDG-avid tumour in most of the cases, suggesting a potential clinical role of (18) F-FDG PET or PET/CT in the initial evaluation of these patients. In particular, the DR of (18) F-FDG PET or PET/CT is related to the primary site of the MALT lymphoma.

Published
2014

Catalog

Books, media, physical & digital resources
See catalog results